Functional Outcomes After Localized Prostate Cancer Treatment
Bashir Al Hussein Al Awamlh(Cornell University), Daniel A. Barocas(Vanderbilt University Medical Center), Ralph Conwill(Vanderbilt-Ingram Cancer Center), David F. Penson(Geriatric Research Education and Clinical Center), Ruchika Talwar(Vanderbilt University Medical Center), Tatsuki Koyama(Vanderbilt University Medical Center), Alicia K. Morgans(Dana-Farber Cancer Institute), Lisa E. Paddock(Rutgers, The State University of New Jersey), Li‐Ching Huang(Vanderbilt University), Xiao‐Cheng Wu(London School of Hygiene & Tropical Medicine), Christopher J.D. Wallis(University Health Network), Ann S. Hamilton(University of Southern California), Brock B. O’Neil(University of Utah), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Zhiguo Zhao(Vanderbilt University), Michael Goodman(Emory University)
Cited by 97
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694